2月6日,NMPA官网显示,科伦博泰TROP2 ADC芦康沙妥珠单抗获批一项新适应症,用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性(HR+)且人表皮生长因子受体2阴性(HER2-)乳腺癌(BC)成人患者。此前该适应症已被 CDE 纳入优先审评审批程序。芦康沙妥珠单抗是科伦博泰研发的一款靶向TROP2的ADC药物,由人源化单克隆抗体 ...
Source Link2月6日,NMPA官网显示,科伦博泰TROP2 ADC芦康沙妥珠单抗获批一项新适应症,用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性(HR+)且人表皮生长因子受体2阴性(HER2-)乳腺癌(BC)成人患者。此前该适应症已被 CDE 纳入优先审评审批程序。芦康沙妥珠单抗是科伦博泰研发的一款靶向TROP2的ADC药物,由人源化单克隆抗体 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.